Connect with us

BUSINESS

Tetra Bio Pharma Inc (OTCMKTS:TBPMF) Issues An Update On The Tolerability, Safety, And Efficacy Of PPP003 Opthalmic Drug To Treat Eye Pain In Animals

Published

on

Tetra Bio Pharma Inc (OTCMKTS:TBPMF) has issued an update on the clinical trial of the PPP003 Ophthalmic drug to treat eye pain in companion animals. During the evaluation trial, the company will ascertain the tolerability, safety, and efficiency of the drug in curing eye pain.

Invests in sterile cannabinoid drug manufacturing suite

Tetra Bio has invested in establishing a sterile cannabinoid drug manufacturing suite in New Brunswick after receipt of the approval from Health Canada in the year 2019. The company has manufactured batches of PPP003 drug at this production facility for ophthalmic drug development.

Design of sterile suite

The quality compliance and manufacturing staff of Tetra Bio has performed the implementation of the cGMPs, and design of the sterile suite, and validated the sterile process. Tetra Bio will use the validated sterile drug batches in the clinical trial in companion animals that suffer from indolent corneal ulcers. The company will begin the clinical trial this year. It needs to follow a similar production process to manufacture drugs for clinical trials in humans to treat eye diseases that include uveitis and painful dry eye.

Chief Regulatory Officer and Chief Executive Officer of Tetra Bio, Dr. Guy Chamberland, said the company is excited to create and validate the production facility to manufacture sterile drugs for the development of ophthalmic drugs. The US FDA validated the ophthalmic research program in June 2019. It is a significant milestone for the company to launch the clinical trial of PPP003 on humans later this year, being a priority, along with its PPP001 and PPP01 drug development programs. The company expects to satisfy the demand for unmet medical needs of ophthalmic drugs in humans and companion animals. Tetra Bio has selected PPP003 because it is a non-regulated cannabinoid.

The market for companion animal healthcare across the world is $46 billion in 2018 and expects to reach $67 billion by the end of 2025, growing at a CAGR of 5.56% between 2019 and 2025.

Tetra Bio is pleased to announce a favorable response from the US FDA for its CAUMZ. It is on the backdrop of the company’s Type B meeting the US FDA for CAUMZ previously.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

BUSINESS

Cannabis Hubs Push for Growth (CNFA, GTBIF, TCNNF, LHSIF)

Published

on

Expansion continues in the cannabis patch, with organic footprint growth among many of the leaders in the space, even as the pandemic rages on. That expansion takes different forms for different leading names. But the overall picture remains one of high-ROI assumptions.

We look at several of the most active names in the space here, including: Green Thumb Industries Inc (OTCMKTS:GTBIF), Trulieve Cannabis Corp (OTCMKTS:TCNNF), and Liberty Health Sciences Inc (OTCMKTS:LHSIF). Green Thumb Industries Inc (OTCMKTS:GTBIF) just announced it will open Rise Duncansville, its 47th retail location, on June 30. According to the release, profits from the first day of sales will be donated to Last Prisoner Project, a nonprofit coalition of cannabis industry leaders, executives, and artists dedicated to bringing restorative justice to the cannabis industry. Green Thumb also donated the first day of profits to the Last Prisoners Project when Rise Chambersburg opened in Pennsylvania earlier this month. “We are grateful to create jobs throughout the state as we continue expanding our retail footprint in Pennsylvania during the COVID-19 crisis,” said Green Thumb Founder and Chief Executive Officer Ben Kovler. “The team is also honored to partner with the Last Prisoner Project on the important work of redressing the past and continuing harms of unjust laws and policies so that victimless cannabis prisoners can walk free.”

Green Thumb Industries Inc (OTCMKTS:GTBIF) bills itself as a company that manufactures and sells various cannabis products in the United States. The company’s cannabis products include flower, concentrates for dabbing and vaporizing, edibles, and topicals. The company markets its products through third-party retailers. It also owns and operates a chain of 50 retail stores under the RISE dispensaries name. The company was actually also named a Best Workplace 2018 by Crain’s Chicago Business. It will be interesting to see if the stock can break out of its recent sideways action. Over the past week, the stock is net flat, and looking for something new to spark things. Green Thumb Industries Inc (OTCMKTS:GTBIF) pulled in sales of $138M in its last reported quarterly financials, representing top line growth of 271.9%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($101.8M against $182.5M, respectively).

One key name in the group that deserves some attention is CanaFarma Hemp Products Corp. (CSE:CNFA.CN), a full-service company operating in the hemp industry offering a full range of hemp-related products and services to the consumer wellness market. CanaFarma’s flagship brand is “Yooforic” – ie, like “euphoric”, but with unique spelling – a line of hemp-based CBD-infused products for sale, meeting the highest standards for performance and purity, including gums, tinctures, and creams. 

Even more importantly, the company’s model is driven by a unique marketing model that appears to be growing in terms of traction. Trailing sales and growth are quite strong, and CBD segment is increasingly attractive. We would also note that the hemp-sourced CBD market is growing at an 18.4% Compound Annual Growth Rate (2018-2022), which means it is now outpacing medical and recreational marijuana. This makes sense given that CBD has a much larger total addressable market than does marijuana given that it is not an intoxicant and has the potential to become a mainstream household industry.

 

Trulieve Cannabis Corp (OTCMKTS:TCNNF) just announced the doors of a record 50th location within the State of Florida opened on Friday, June 26th. In other words, one of the fastest expanding distribution forces in the cannabis space is still powering along on a rapid curve.

According to the release, the Ocala location is Trulieve’s 52nd location in the United States, 50 of which are located in the Company’s home state of Florida. Near downtown Ocala, the dispensary supports the Company’s mission to expand and ensure safe, reliable patient access statewide. It also joins Trulieve’s 49 other dispensaries statewide, including in nearby Gainesville, Lady Lake, and Daytona Beach. At approximately 4,400 square feet and with 10 point-of-sale stations, the dispensary will be the Company’s first in Marion County.

Trulieve Cannabis Corp (OTCMKTS:TCNNF) promulgates itself as a company that, through its subsidiary, Trulieve, Inc., engages in the cultivation, possession, distribution, and sale of medical cannabis in the United States.

It offers a suite of Trulieve branded products with approximately 125 SKUs, including nasal sprays, capsules, concentrates, syringes, and cannabis flower in tamper-proof containers for vaporizers, topical creams, tinctures, and vape cartridges.  The company distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as takes orders online and by phone for delivery. As of November 20, 2018, the company operated 21 dispensaries. Trulieve Cannabis Corp. is headquartered in Quincy, Florida. If you’re long this stock, then you’re liking how the stock has responded to the announcement. TCNNF shares have been moving higher over the past week overall, pushing about 4% to the upside on above average trading volume. Trulieve Cannabis Corp (OTCMKTS:TCNNF) managed to rope in revenues totaling $129.2M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 118.5%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($143.5M against $104.7M).

 

Liberty Health Sciences Inc (OTCMKTS:LHSIF) just announced that it has entered into a licensing agreement with licensed California adult use and medicinal cannabis company HONEY, one of California’s largest full service companies, to supply all of Liberty’s dispensaries with the company’s full assortment of branded products. According to the release, in 2012, HONEY revolutionized the cannabis industry by becoming the first producer in the world to market distilled cannabis oil in vape cartridges. Today, they provide authentic, full spectrum oil in vape cartridges, applicators, and caps to legal dispensaries and delivery services.

Liberty Health Sciences Inc (OTCMKTS:LHSIF) frames itself as a company that engages in the production and distribution of medical cannabis primarily in the State of Florida. It has a strategic partnership with Veterans Cannabis Project to support various research projects focused on the treatment of service related trauma with cannabis derived products; and partnership with AdaViv Inc. to enhance production of cannabis. 

The company is headquartered in Toronto, Canada. Liberty Health Sciences was established to own and operate medical marijuana licenses in the United States. To date, the company owns one of 14 licenses issued in the state of Florida as well as 50.1% interest in a provisional processing license and a provisional dispensary license, both in Ohio. Liberty has also made an investment in a provisional medical license in the Commonwealth of Massachusetts.

The stock has suffered a bit of late, with shares of LHSIF taking a hit in recent action, down about -11% over the past week. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -11%.  Liberty Health Sciences Inc (OTCMKTS:LHSIF) generated sales of $17.8M, according to information released in the company’s most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 10.4% on the top line. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($25M against $25.5M, respectively).

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Citation Growth Corp (OTCMKTS:CGOTF) Signs Revised LOI With Indigenomix for Sale of Celista, BC Property

Published

on

Citation Growth Corp (OTCMKTS:CGOTF) and its subsidiary Full Spectrum Medicinal Inc., signed a revised LOI  with Indigenomix regarding the sale of the 40 acres of land in Celista, British Columbia as well as assets on the land.

Citation signs revised LOI with Indigenomix

The companies signed the revised LOI on June 15, representing a reviewed transaction relative to the previous LOI that was executed on April 8, 2020. Following the revised LOI, the companies have terminated the LOI signed on April 8, 2020. Initially, Citation planned for the execution of a Definitive Agreement as per the April 8 LOI before June 15. However, because of travel restriction due to the COVID-19 pandemic, Indigenomix required more time to finalize funding.

Following the changes, the Board of Citation is anticipating the execution of a definitive agreement to be completed on or before 15 days are over following the extension. The companies are working towards meeting terms and conditions of the deal and Citation expects to finalize the transaction within 15 days. The Definitive Agreement also requires Citation to support Indigenomix on some regulatory requirements. Similarly Citation will support Indigenomix on intellectual property license on specific organic cultivation methodologies and other technologies.

Citation sells Lynden, Washington Property

Citation finalized the sale of 13 acres of land and assets in Lynden, Washington, for around $2.5 million. The company which holds a cannabis growing license in Washington State has been looking for options for optimizing the license or selling it completely.

Erik Anderson, the CEO of the company, stated that the company’s new management team’s strategic review considered Lynden property as non-core assets. The company is looking to sell its non-core assets as part of its strategic refocus on California and Nevada markets. Citation was fortunate to sell the property to a confidential buyer, especially considering the restrictions due to COVID-19.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Zelira Therapeutics Ltd (OTCMKTS:ZLDAF) Signing Nonbinding Agreement With Levin Growing To Develop Cannabinoid Based Chronic Pain Treatment

Published

on

Zelira Therapeutics Ltd (OTCMKTS:ZLDAF) has signed a nonbinding agreement with Levin Growing Pty Ltd for the establishment of a development partnership.

Partnership to develop chronic pain treatment

The company will partner with the Melbourne-based medical cannabis firm to develop a proprietary cannabinoid-based chronic pain treatment in retired and amateur athletes studies, retired athletes are likely to experience chronic pain related to conditions like anxiety and depression due to injuries and physical exertion over lengthy periods. Although there is limited clinical data on medical cannabis as an effective and safe targeted treatment option the cannabinoid-based therapy is likely to benefit retired athletes significantly.

Partnership between Zelira and Levin seeks to conduct clinical trials to address this unmet need. They will undertake the trial at the expense of Levin to evaluate the efficacy and safety of a novel cannabinoid formulation customized for sports-associated chronic pain. The collaboration will exploit the leading intellectual property as well as expertise of Zelira in medical cannabis clinical design. The targeted approach offers a chance to develop a leading brand addressing this widespread and specific unmet need.

Zelira to control marketing rights for North and South America

After the Heads of Agreement becomes binding, Zelira will license a particular formulation to Levin supporting the chronic pain trial in retired sportsmen. Zelira will design and co-ordinate the clinical study with funding from Levin. The study is an expansion of the strategic interests of Zelira in chronic pain. Zelira will control commercialization rights in South America and North America while Levin will retain rights to the rest of world markets.

Levin Chairman, Matt Syme, stated that they are thrilled in the partnership with Zelira, one of the top medical cannabis companies. Syme indicated that the company’s advisory board member and sports administrator, James Brayshaw, has identified various retired athletes suffering from chronic pain. He added that the clinical expertise of Zelira and Levin’s focus on medical cannabis science as a chronic pain treatment gives hope of having a non-addictive paint relieve alternative.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories